COTI-2, a potent orally available small molecule targeting mutant p53, with promising efficacy as monotherapy and combination treatment in preclinical tumor models.

6040Background: The p53 tumor suppressor is mutated in more than half of all cancers. COTI-2, an oral 3rd-generation thiosemicarbazone, restores the structure and function of mutant p53 proteins an...